Skip to main content
SpringerLink
Log in

Infectious complications and mortality associated with the use of IV iron therapy: a systematic review and meta-analysis

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

Parental iron is used to optimize hemoglobin and enhance erythropoiesis in end-stage renal disease along with erythropoietin-stimulating agents. Safety of iron has been debated extensively and there is no definite evidence whether parenteral iron increases the risk of infections and mortality. We performed this meta-analysis to evaluate the incidence of infectious complications, hospitalizations and mortality with use of parenteral iron.

Methods

Medical electronic databases [PubMed, EMBASE, Scopus, Web of Science, and cochrane central register for controlled clinical trials (CENTRAL)] were queried for studies that investigated the association between intravenous iron administration and infection in hemodialysis patients. 24 studies (8 Randomized control trials (RCTs) and 16 observational studies) were considered for qualitative and quantitative analysis.

Results

All-cause mortality Data from 6 RCTs show that high-dose IV iron conferred 17% less all-cause mortality compared to controls; however, this outcome was not statistically significant (OR = 0.83, CI [0.7, 1.01], p = 0.07). Nine observational studies were pooled under the random effects model due to significant heterogeneity (I2 = 83%, p < 0.001). The overall HR showed increased risk of all-cause mortality in the high-dose group but was statistically non-significant (HR = 1.1, CI [1, 1.22], p = 0.06). Infections Four RCTs with no heterogeneity among their data (I2 = 0%, p = 0.61). Under the fixed effect model, there was no difference in the infection rate between high-dose iron and control group (OR = 0.97, CI [0.82, 1.16], p = 0.77); eight observational studies with significant heterogeneity and utilizing random effects model. Summary HR showed increased yet non-significant risk of infection in the high-dose group (HR = 1.13, CI [0.99, 1.28], p = 0.07) Hospitalization 1 RCT and six observational studies provided data for the rate of all-cause hospitalization. There was marked heterogeneity among observational studies. RCT showed no significant difference between high-dose iron and controls in the rate of hospitalization (OR = 1.03, CI [0.87, 1.23], p = 0.71). Summary HR for observational data showed increased rate of hospitalization in the high-dose group; however, this effect was not statistically significant (HR = 1.11, CI [0.99, 1.24], p = 0.07). Cardiovascular events One RCT compared the rate of adverse cardiovascular events between high-dose and low-dose iron. No significant difference was observed between the two groups (22.3% vs 25.6%, p = 0.12). Six heterogeneous observational studies (I2 = 65%, p < 0.001) reported on the rate of cardiovascular events. No significant difference was observed between high-dose iron and controls (HR = 1.18, CI [0.89, 1.57], p = 0.24).

Conclusion

High-dose parenteral iron does not seem to be associated with higher risk of infection, all-cause mortality, increased hospitalization or increased cardiovascular events on analysis of RCTs. Observational studies show increased risk for all-cause mortality, infections and hospitalizations that were not statistically significant and were associated with significant heterogeneity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jha V, Modi GK (2018) Getting to know the enemy better—the global burden of chronic kidney disease. Kidney Int 94(3):462–464

    Article  PubMed  Google Scholar 

  2. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F et al (2004) Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 44(1):94–111

    Article  PubMed  Google Scholar 

  3. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Supplement 1):S4–S8

    Article  CAS  PubMed  Google Scholar 

  4. Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23(10):1631–1634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hörl WH (2002) Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transpl 17(suppl_11):35–38

    Article  Google Scholar 

  6. Moore LL, Humbert JR (1984) Neutrophil bactericidal dysfunction towards oxidant radical-sensitive microorganisms during experimental iron deficiency. Pediatr Res 18(8):789–794

    Article  CAS  PubMed  Google Scholar 

  7. Macdougall IC, Bircher AJ, Eckardt K-U, Obrador GT, Pollock CA, Stenvinkel P et al (2016) Iron management in chronic kidney disease: conclusions from a “kidney disease: improving global outcomes”(KDIGO) controversies conference. Kidney Int 89(1):28–39

    Article  CAS  PubMed  Google Scholar 

  8. Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A (2016) Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis 68(5):677–690

    Article  CAS  PubMed  Google Scholar 

  9. Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P et al (2018) Safety of intravenous iron in dialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 13(3):457–467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA et al (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447–458

    Article  CAS  Google Scholar 

  11. Higgins JP, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions. Wiley

  12. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269

    Article  Google Scholar 

  13. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928

    Article  PubMed  PubMed Central  Google Scholar 

  14. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605

    Article  Google Scholar 

  15. Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB, Group USISCT (2006) Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol 1(3):475–482

    Article  CAS  PubMed  Google Scholar 

  16. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ (2009) Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 4(2):386–393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJ, Murray H, Tomson CR, Wheeler DC, Winearls CG (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447–458

    Article  CAS  Google Scholar 

  18. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L (1998) Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 79(3):299–305

    Article  CAS  PubMed  Google Scholar 

  19. Fishbane S, Frei GL, Maesaka J (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26(1):41–46

    Article  CAS  PubMed  Google Scholar 

  20. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV et al (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to iv Iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 18(3):975–984

    Article  CAS  PubMed  Google Scholar 

  21. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S et al (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11(3):530–538

    CAS  PubMed  Google Scholar 

  22. Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL et al (2014) Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transpl 30(4):667–675

    Article  CAS  Google Scholar 

  23. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B et al (2015) Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int 87(1):162–168

    Article  CAS  PubMed  Google Scholar 

  24. Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG, Crews DC, Scialla JJ (2014) Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 9(11):1930–1939

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA (2014) Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study. BMC Nephrol 15(1):154

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA (2013) Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 8(11):e78930

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV (2013) Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24(7):1151–1158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kuo K-L, Hung S-C, Lin Y-P, Tang C-F, Lee T-S, Lin C-P et al (2012) Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One 7(12):e50295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pollak VE, Lorch JA, Shukla R, Satwah S (2009) The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol 10(1):6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R et al (2008) Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19(2):372–379

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kopelman RC, Smith L, Peoples L, Biesecker R, Rizkala AR (2007) Functional iron deficiency in hemodialysis patients with high ferritin. Hemodial Int 11(2):238–246

    Article  PubMed  Google Scholar 

  32. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG (2005) Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16(10):3070–3080

    Article  CAS  PubMed  Google Scholar 

  33. Varas J, Ramos R, Aljama P, Pérez-García R, Moreso F, Pinedo M et al (2017) Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: a propensity-score matched approach. Nephrol Dial Transpl 33(1):160–170

    Article  CAS  Google Scholar 

  34. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W et al (2004) Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15(6):1623–1632

    Article  CAS  PubMed  Google Scholar 

  35. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M et al (2002) Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13(3):734–744

    CAS  PubMed  Google Scholar 

  36. Hoen B, Paul-Dauphin A, Kessler M (2002) Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 57(6):457–461

    Article  CAS  PubMed  Google Scholar 

  37. Canziani MEF, Yumiya ST, Rangel EB, Manfredi SR, Neto MC, Draibe SA (2001) Risk of bacterial infection in patients under intravenous iron therapy: dose versus length of treatment. Artif Organs 25(11):866–869

    Article  CAS  PubMed  Google Scholar 

  38. Fülöp T, Tapolyai MB, Agarwal M, Lopez-Ruiz A, Molnar MZ, Dossabhoy NR (2017) Bedside tunneled dialysis catheter removal—a lesson learned from nephrology trainees. Artif Organs 41(9):810–817

    Article  PubMed  Google Scholar 

  39. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT et al (2015) Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 26(2):493–503

    Article  CAS  PubMed  Google Scholar 

  40. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J et al (2015) Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol 26(10):2578–2587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A (2015) The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 90(1):12–23

    Article  CAS  PubMed  Google Scholar 

  42. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U (2008) Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 52(5):897–906

    Article  CAS  PubMed  Google Scholar 

  43. Susantitaphong P, Alqahtani F, Jaber BL (2014) Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 39(2):130–141

    Article  CAS  PubMed  Google Scholar 

  44. Robinson BM, Larkina M, Bieber B, Kleophas W, Li Y, Locatelli F et al (2017) Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the dialysis outcomes and practice patterns study (DOPPS). BMC Nephrol 18(1):330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A (2015) Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int 88(5):1187–1194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Fishbane SN, Singh AK, Cournoyer SH, Jindal KK, Fanti P, Guss CD et al (2015) Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transpl 30(12):2019–2026

    Article  CAS  Google Scholar 

  47. Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A (2014) Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 86(4):845–854

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216-4505, USA

    Sohail Abdul Salim & Wisit Cheungpasitporn

  2. Al-Razi Medical Research Academy, Cairo, Egypt

    Ahmad Elmaraezy

  3. Computational and Data-Enabled Science, Jackson State University, Jackson, MS, USA

    Omar Jawafi & Md Rahman

  4. Deaconess Health System, Evansville, IN, USA

    Narothama Reddy Aeddula

  5. Keystone Health, Chambersburg, PA, USA

    Raghavendra Tirupathi

  6. Division of Nephrology, Department of Internal Medicine, Medical University of South Carolina, Charleston, SC, USA

    Tibor Fülöp

  7. Raph H. Johnson VA Medical Center, Charleston, SC, USA

    Tibor Fülöp

Authors
  1. Sohail Abdul Salim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wisit Cheungpasitporn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmad Elmaraezy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Omar Jawafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Md Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Narothama Reddy Aeddula
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raghavendra Tirupathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tibor Fülöp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohail Abdul Salim.

Ethics declarations

Conflict of interest

The authors alone are responsible for the content and writing of the paper. The authors have no disclosures or conflicts of interest to report. This study did not receive any research funding.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salim, S.A., Cheungpasitporn, W., Elmaraezy, A. et al. Infectious complications and mortality associated with the use of IV iron therapy: a systematic review and meta-analysis. Int Urol Nephrol 51, 1855–1865 (2019). https://doi.org/10.1007/s11255-019-02273-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-019-02273-4

Keywords

Search

Navigation